The interaction of tumor necrosis factor a (TNF) with its two membrane-bound receptors initiates intracellular events in which arachidonic acid and its derivatives are involved. In HeLa cells, TNF treatment induces an arachidonic acid-selective, Ca2+-dependent cellular phospholipase A2 (cPLA2). By itself, TNF causes a modest increase in cPLA2 activity, but with the Ca2+ ionophore A23187 it provides a strong synergistic action. Within minutes in response to TNF, cPLA2 becomes phosphorylated and in the presence of Ca2+ produces a 3-to 4-fold increase in activity. TNF also increases cPLA2 mRNA and protein expression, an estimated 5-fold increase in an 8-hr period. This increase in cPLA2 activity occurs, therefore, in a biphasic time-dependent manner. Dexamethasone, known to antagonize the action of TNF, is here shown to inhibit TNF-induced gene expression and to prevent the second phase of increase in cPLA2 activation. Our results suggest that the cPLA2 activation may provide a regulatory function and may explain the proinflammatory action of TNF.
Tumor necrosis factor alpha (TNF) is a multifunctional cytokine produced mainly by monocytes and macrophages (1) . TNF is now considered to be one of the major "inflammatory" cytokines, playing an essential role as an immunostimulant to increase host defense mechanisms against infections (2) . In this role, TNF induces the production of prostaglandins, leukotrienes, and platelet-activating factor, which serve as inflammatory mediators. Therefore, a variety of events are initiated through the interaction of TNF with its membrane-bound receptors. The presence of two divergent receptors (3) (4) (5) (6) and the multiple effects of TNF suggest that various functions of TNF may be mediated by coupled or independent receptor-activated signal transduction pathways (7) .
Early events of TNF-mediated signal transduction appear to involve lipids as mediators (8) (9) (10) (11) (12) (13) (14) (15) (16) . For example, TNF stimulates the release of arachidonic acid (AA) from a variety of cell types (11) (12) (13) , and AA-depleted cells are less susceptible to the cytotoxic effects ofTNF (14) . The induction ofthe protooncogene c-fos by TNF is mediated through lipoxygenase products of AA (15) , which are also required for TNF-cycloheximide-induced cytotoxicity (16) . Since AA metabolites such as prostaglandins and leukotrienes play an important role in inflammation (17, 18) , the proinflammatory properties of TNF could be ascribed to its ability to release AA. Of the several enzymatic pathways responsible for the release of AA, which is esterified to the sn-2 position of phospholipids, phospholipase A2 is an important enzyme for this hydrolytic cleavage reaction (18, 19) . Thus, one possibility is that AA release by TNF is mediated through its effect on PLA2.
Phospholipase A2 enzymes can be grouped into two classes based on their molecular weight and cellular distribution. The "'14-kDa small molecular weight granule-associated secretory PLA2 (sPLA2) enzymes are rich in disulfide bonds, require millimolar levels of Ca2+ for activity, but display no apparent selectivity for AA-containing phospholipids. They presumably play a role in inflammation, digestion, and scavenging and are induced by TNF (20) (21) (22) (23) . On the other hand, the recently described and cloned high molecular weight cytosolic PLA2 (cPLA2) selectively liberates AA from the sn-2 position of membrane phospholipids (24) (25) (26) (27) (28) and is coupled to ligand-regulated AA release (29) . Therefore, it is an important enzyme for the biosynthesis of prostaglandins and leukotrienes. Here, we demonstrate that receptormediated AA release occurs by TNF. TNF treatment phosphorylates cPLA2 and with the Ca2+-ionophore A23187 causes a biphasic release of AA. The initial rapid increase in activity correlates with the phosphorylation of the protein, and the second rapid increase correlates with the synthesis of new cPLA2. The antiinflammatory glucocorticoid dexamethasone does not block TNF-induced cPLA2 phosphorylation, but it inhibits TNF-induced cPLA2 synthesis.
MATERIALS AND METHODS
Cell Culture and PLA2 Assays. HeLa cells were grown as described (7) . Assays to determine the activity of sPLA2 in the culture medium and cPLA2 in cell extracts were performed as described (30 
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The publication costs of this article were defrayed in part by page charge payment. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. §1734 solely to indicate this fact. lysis buffer (50 mM Tris HCl, pH 7.8/1% Triton X-100/0.1% SDS/250 mM NaCl/5 mM EDTA) and centrifuged. The supernatant was immunoprecipitated with 2 ,ul of either normal rabbit serum or anti-cPLA2 antiserum (29) , and the antigen-antibody complexes adsorbed to protein A-Sepharose were resolved by SDS/polyacrylamide gel electrophoresis.
Immunoblotting. Total cell extracts were prepared as described above. Protein concentration was determined by using the Pierce BCA (Bradford Coomassie assay) protein assay; 200 ,g of protein per lane was resolved in 9% SDS/polyacrylamide gels and blotted to Immobilon membranes (Millipore). Incubation with cPLA2 antibodies was performed and antigen-antibody complexes were visualized by using the nonradioactive electrochemiluminescence (ECL) detection kit (Amersham).
RNA Blot Analysis. Northern blot analysis on HeLa cell total RNA was performed (3). Hybridization buffer contained 4 x 106 cpm of cPLA2 riboprobe per ml prepared from a Sal I fragment containing the majority of the cPLA2 coding sequence obtained from the plasmid pMT2-hcPLA2 (Genetics Institute, Boston) and cloned into the plasmid pGEM-3Z (Promega).
RESULTS
TNF and A23187 Increase AA Release. Phospholipase A2 enzyme activity was measured by the release of [3H]AA from prelabeled HeLa cells. The prelabeled cells at >90% confluency were incubated in DMEM/0.5% FCS growth medium in the presence or absence of 50 ng of TNF per ml, and the release of 3H into the medium was determined after the indicated periods of time. A significant increase in the release of [3H]AA was evident in 2 h after TNF addition, and the release continued to increase gradually over a 6-h period ( Fig.  1 Top). Considering the nature of the experiment, which measures a total increase in [3H]AA in the medium and includes the spontaneous release of radiolabel by the cells, the sensitivity of the assay is limited for measuring small increases in activity. Our results indicate that it takes a couple of hours for the increased activity to become evident, and this consistent increase becomes more obvious with time. We also have assayed the growth medium of unlabeled HeLa cells under similar conditions for secreted PLA2 activity, but no increase in the medium was observed over a 4-h period (data not presented).
Since the requirement of PLA2 enzymes for Ca2+ has been well documented (24, (28) (29) (30) has long been believed to occur via inhibition ofPLA2 activity (31) . Therefore, we tested the action of the synthetic glucocorticoid dexamethasone, and Fig. 1 Bottom (dashed line) shows that dexamethasone did not reduce the amount of AA released within 15 min of treatment but did block the second phase of prolonged increase in AA released from the cells. Also, dexamethasone was without effect on the AA released by A23187 alone.
cPLA2 Phosphorylation Occurs Within Minutes of TNF Treatment. It has been demonstrated (29) that cPLA2 is phosphorylated in response to a wide variety of agonists and that this phosphorylation correlates with increased cPLA2 activity. We have confirmed these observations with TNF. Since phosphorylated proteins show altered migration patterns on SDS/PAGE gels relative to their nonphosphorylated counterparts (29), we also analyzed the mobility of cPLA2 in response to TNF. In cytoplasmic extracts of resting HeLa cells, analyzed by immunoblot analysis, cPLA2 protein was observed as a doublet of two equal intensity bands ( Fig. 2A,  forms I and II) . TNF treatment caused a complete shift to the upper more slowly migrating form (form II) within 20 min at concentrations ranging between 1 and 10 ng/ml (data not shown). Addition of the ionophore A23187 alone had no effect ( Fig. 2A, last lane) . Whether this shift was due to the phosphorylation of the protein was tested by in vivo [32P]orthophosphate labeling of HeLa cells. The cPLA2 protein was isolated by immunoprecipitation and analyzed by gel electrophoresis and autoradiography. The immunoprecipitated cPLA2 from untreated HeLa cells (Fig. 2B Upper panel, lanes 2 and 4) was phosphorylated, and TNF treatment for 20 min caused an 1.5-to 2-fold increase in the 32p incorporated into cPLA2, which was observed as an increase in band intensity (Fig. 2B, lane 3) . Normal rabbit serum did not immunopre- cipitate any phosphorylated proteins (Fig. 2B, lane 1) . In an identical experiment, cells were not radiolabeled, and an immunoblot of their extract was superimposed on the autoradiograph of the phosphorylated material (Fig. 2B Lower  panel) . Only the upper band of the cPLA2 doublet was phosphorylated (form II), and TNF caused an increase in 32p incorporation as well as a complete shift of the cPLA2 protein into this upper, slower migrating species. Since previous reports had suggested that glucocorticoids may induce serine/ threonine protein phosphatases and dephosphorylate and inactivate PLA2 (31, 32), we analyzed cells in the presence or absence of dexamethasone for the TNF-induced shift of cPLA2 protein (Fig. 2C) . Alone or in combination with TNF, dexamethasone failed to alter the migration of cPLA2 protein. Therefore, at least in HeLa cells, dexamethasone does not alter the level of cPLA2 phosphorylation.
TNF Increases Expression of cPLA2 mRNA in a Time-and Concentration-Dependent Manner. To examine the molecular basis for the second more prolonged increase in AA release, we analyzed the expression of cPLA2 mRNA. TNF was added to HeLa cells for different periods of time, and total RNA was analyzed by Northern blots. A time-dependent increase in cPLA2 mRNA expression was seen with the earliest visible increase occurring within 3 h of treatment (Fig. 3 Left). In 8 h, an -4-fold increase in steady-state mRNA levels was observed, which was maintained for up to 18 h. We have also analyzed other cell lines, such as the mouse adipogenic TAl cells and NIH 3T3 cells, and these too showed TNF induction of cPLA2 mRNA (data not shown). In a TNF dose-response, concentrations between 5 and 10 ng/ml were adequate for the 4-fold increase in cPLA2 mRNA (Fig. 3 Right), and these concentrations of TNF are well within a physiological range required to elicit the various functions associated with this cytokine.
TNF Also Increases the Total Amount of cPLA2 Protein in HeLa Cells. The TNF-induced increase in cPLA2 mRNA expression was reflected in a parallel increase in its protein level. In immunoblot analysis of cytoplasmic extracts of TNF-treated cells, a gradual increase in cPLA2 protein (Fig.  4) was evident between 3 and 6 h of treatment and by 18 h had increased 3-to 4-fold. Again, this increase in cPLA2 protein levels was TNF dose dependent (data not shown); therefore the induction of both cPLA2 mRNA and protein occurs concomitantly.
Dexamethasone Antagonizes the TNF-induced Increase in cPLA2 mRNA Levels. In experiments described above (Fig. 1 Bottom), dexamethasone had prevented the second phase of increase in cPLA2 activity by TNF but was without effect on cPLA2 phosphorylation (Fig. 2C) . To explore the glucocorticoid-dependent inhibition of cPLA2 activity, the effect of dexamethasone on cPLA2 mRNA expression was examined. In total RNA isolated from HeLa cells treated for 18 h with 50 ng of TNF per ml plus various concentrations of dexamethasone, the TNF-induced cPLA2 expression was inhibited (Fig. 5) . The inhibition occurred at concentrations of 10 and 100 nM and was also observed with the natural glucocorticoid hydrocortisone. Other steroid hormones, like estrogens or progestins, had no effect. In addition, dexamethasone also appeared to slightly suppress the basal level of cPLA2 mRNA. DISCUSSION
A number of laboratories have provided evidence for the participation of AA and/or its metabolites in receptorcoupled intracellular signaling pathways (33, 34) . We have previously demonstrated that the release of AA is a critical step in some of the TNF signaling pathways (14) and that the induction of the protooncogene c-fos by TNF is mediated by lipoxygenase products of AA (15 cycloheximide-induced cytotoxicity as well as the induction of manganous superoxide dismutase (16) . Since AA is exclusively esterified to membrane phospholipids and is released mainly by the action of PLA2, it was likely that the AA released by TNF involved PLA2 action. Since the cytosolic PLA2 had been shown to be highly specific for the release of AA (29) and was hormonally regulated (24, 27, 29) , we chose to investigate the activation of this cPLA2 by TNF.
The data presented here demonstrate that TNF in a dosedependent manner increases cPLA2 activity by two separate mechanisms. A more immediate action of TNF on cPLA2 appears to be a phosphorylation of the enzyme, while a long-term effect constitutes a sustained production of new cPLA2.-Phosphorylation by itself causes only a modest increase in cPLA2 activity (29) , and the gradual increase in PLA2 activity by TNF alone possibly reflects this action on newly synthesized cPLA2 protein. In the presence of Ca2+, however, a 3-to 5-fold increase in AA release is observed within 15 min of TNF treatment, and this increase correlates well with the phosphorylation of cPLA2 protein. Thus, it appears that only a modest increase in activity occurs via phosphorylation, but a far more enhanced PLA2 activity is caused when Ca2+ is provided. Similar observations for a Ca2+ requirement were reported for phorbol 12-myristate 13-acetate (PMA)-induced cPLA2 activity in Chinese hamster ovary cells (29) and TNF-stimulated human neutrophils (35) . The term "primed stimulation" was used to describe the initial treatment with TNF that responded synergistically to a second agent such as the chemotactic peptide phenylalanylmethionylarginyl-phenylaninamide (FMLP; ref. 35) or calcium ionophores (36) . We now believe this priming action by TNF to be the phosphorylation of cPLA2. Therefore at sites ofinflammation it is conceivable that the other growth factors and cytokines, by stimulating Ca2+ release, provide the synergistic action with TNF to cause an exaggerated PLA2 response and the ensuing inflammatory reactions. TNF is known to alter the phosphorylation state ofa number of proteins (37) . Dressler et al. (9) have recently described a ceramide-activated serine/threonine protein kinase involved in the TNF signaling pathway. This kinase belongs to a family ofprotein kinases with specificity similar to mitogen-activated protein 2 (MAP2) kinases (38) , and purified cPLA2 has been shown to be phosphorylated and activated by a MAP2 kinase in vitro (44) . Whether the phosphorylation of cPLA2 by TNF is induced by this pathway to provide the priming function remains to be determined.
The long-term stimulation of AA release from HeLa cells correlates well with the TNF induction of cPLA2 message as well as cPLA2 protein. The exact nature of the effect of TNF on cPLA2 gene induction is not known. Earlier TNF has been shown to activate a variety of transcription factors (15, 39) , and only an examination of the cPLA2 promotor/enhancer sequences will provide information of this transcriptional control and factors involved. Glucocorticoids here certainly appear to act via inhibition of cPLA2 gene expression. However, their well-known antiinflammatory properties are ascribed to their ability to inhibit PLA2 activity via induction of phospholipid-binding proteins, called lipocortins (40) , and of protein phosphatases (31, 32) . Recent reports have questioned the involvement of lipocortins (41) 
